The estimated Net Worth of Scott Dahlbeck is at least $907 ezer dollars as of 23 May 2022. Dr Dahlbeck owns over 17,240 units of Kiromic BioPharma stock worth over $906,917 and over the last 2 years he sold KRBP stock worth over $0.
Dr has made over 1 trades of the Kiromic BioPharma stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 17,240 units of KRBP stock worth $34,997 on 23 May 2022.
The largest trade he's ever made was exercising 17,240 units of Kiromic BioPharma stock on 23 May 2022 worth over $34,997. On average, Dr trades about 8,620 units every 0 days since 2022. As of 23 May 2022 he still owns at least 446,757 units of Kiromic BioPharma stock.
You can see the complete history of Dr Dahlbeck stock trades at the bottom of the page.
Dr. Scott Dahlbeck Pharm.D., M.D., PharmD is the Chief Medical Officer at Kiromic BioPharma.
Dr PharmD is 59, he's been the Chief Medical Officer of Kiromic BioPharma since . There are no older and 5 younger executives at Kiromic BioPharma.
Scott's mailing address filed with the SEC is C/O KIROMIC BIOPHARMA, INC., 7707 FANNIN, SUITE 140, HOUSTON, TX, 77054.
Over the last 4 years, insiders at Kiromic BioPharma have traded over $0 worth of Kiromic BioPharma stock and bought 29,599 units worth $105,539 . The most active insiders traders include Jerry A. Schneider, Scott Dahlbeck és Pietro Bersani. On average, Kiromic BioPharma executives and independent directors trade stock every 99 days with the average trade being worth of $7,923. The most recent stock trade was executed by Pietro Bersani on 23 August 2024, trading 3,488 units of KRBP stock currently worth $7,395.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Kiromic BioPharma executives and other stock owners filed with the SEC include: